Synthesis and biological activity of P2-P4 azapeptidomimetic P1-argininal and P1-ketoargininamide derivatives: A novel class of serine protease inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 3, 1997, Pages 315-320

  Sample, J Edward ^a   Rowley, David C ^a   Brunck, Terence K ^a   Ripka, William C ^a  

^a Dendreon   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE DERIVATIVE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; PLASMIN; SERINE PROTEINASE INHIBITOR; THROMBIN; TRYPSIN;

ARTICLE; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; HEMOSTASIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

EID: 0031552099     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)00005-X     Document Type: Article

References (40)

1. 1. Dedicated with genuine affection and respect to Professor Madeleine M. Joullie, Department of Chemistry, University of Pennsylvania, on the occasion of her 70th birthday.
2. 2. Han, H.; Janda, K. J. Am. Chem. Soc. 1996, 118, 2539.
3. 3. Fassler, A.; Bold, G.; Capraro, H.-G.; Cozens, R. Mestan, J.; Poncioni, B.; Rosel, J.; Tintelnot-Blomley, M.; Lang, M. J. Med. Chem. 1996, 39, 3203.
4. 4. Andre, F.; Marraud, M.; Boussard, G. Tetrahedron. Lett. 1996, 37, 183.
5. 5. Portions of this work were presented at the Biological Challenges for Organic Chemistry Symposium; Royal Society of Chemistry; St. Andrews, Scotland; July 10-13, 1995; Poster P.68.
6. 6. (a) Gante, J. Synthesis 1989, 405.
7. (b) Dutta, A. S.; Morley, J. S. J. Chem. Soc. Perkin Trans. I 1975, 1712.
8. 7. (a) Colman, R. W.; Marder, V. J.; Salzman, E.; W. Hirsch, J. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice ; 3rd ed.; Colman, R. W.; Hirsch, J.; Marder, V. J.; Salzman, E. W.; Eds.; J. B. Lippincott: Philadelphia, 1994; 3.
9. 7. (a) Colman, R. W.; Marder, V. J.; Salzman, E.; W. Hirsch, J. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice ; 3rd ed.; Colman, R. W.; Hirsch, J.; Marder, V. J.; Salzman, E. W.; Eds.; J. B. Lippincott: Philadelphia, 1994; 3.
10. (b) Mann, K. G. ibid., 184.
11. (c) Colman, R. W.; Cook, J.; Niewiarowski, S. ibid., 508.
12. (d) Edit, J. F.; Allison, P.; Noble, S.; Ashton, J.; Golino, P.; McNard, J.; Buja, L. M.; Willerson, J. T. J. Clin. Invest. 1989, 84, 18.
13. 8. (a) Bazan, J. F. Nature 1996, 380, 21.
14. (b) Tapparelli, C.; Meternich, R.; Ehrhardt, C.; Cook, N. S. Trends Pharm. Science 1993, 14, 366.
15. (c) Maraganore, J. M. Thromb. Haemostasis 1993, 70, 208.
16. (d) Tans, G.; Rosing, J.; Thomassen, M. C.; Heeb, M. J.; Zwaal, R. F.; Griffin, J. H. Blood 1991, 77, 2641.
17. 9. (a) Scarborough, R. M. In Ann. Rep. Med. Chem. Bristol, J. A., Ed.; Academic Press: San Diego, 1995; vol. 30, 71.
18. (b) Harker, L. A.; Hanson, S. R.; Kelly, A. B. Thromb. Haemost. 1995, 74, 464.
19. (c) Lyle, T. A. Perspectives in Drug Discovery and Design 1993, 1, 453.
20. 1 see: Balasubramanian, B. N., Ed.; Advances in the Design and Development of Thrombin Inhibitors. Bioorg. Med. Chem. 1995, 3, 999-1156.
21. 11. (a) Semple, J. E.; Rowley, D. C.; Brunck, T. K.; Ha-Uong, T.; Minami, N. K.; Owens, T. D.; Tamura, S. Y.; Goldman, E. A.; Siev, D. V.; Ardecky, R. J.; Carpenter, S. H.; Ge, Y.; Richard, B. M.; Nolan, T. G.; Håkanson, K; Tulinsky, A.; Nutt, R. F.; Ripka, W. C. J. Med. Chem. 1996, 39, in press
22. (b) Cousins, G. R.; Friedrichs, G. S.; Sudo, Y.; Rebello, S. S.; Rote, W. E.; Vlasuk, G. P.; Nolan, T. G.; Mendoza, C.; Lucchesi, B. R. Circulation 1996, 94, 1705.
23. 12. (a) Bagdy, D.; Barabas, E.; Bajusz, S.; Szell, E. Thromb. Haemostasis 1992, 67, 325.
24. (b) Shuman, R. T.; Rothenberger, R. B.; Campbell, C. S.; Smith, G. F.; Gifford-Moore, D. S.; Paschal, J. W.; Gesellchen, P. D. J. Med. Chem. 1995, 38, 4446.
25. (c) Håkansson, K.; Tulinsky, A.; Abelman, M. M.; Miller, T. A.; Vlasuk, G. P.; Bergum, P. W.; Lim-Wilby, M. S. L.; Brunck, T. K. Bioorg. Med. Chem. 1995, 3, 1009.
26. 13. (a) Banner, D. W.; Hadvary, P. J. Biol. Chem. 1991, 266, 20085.
27. (b) Bode, W.; Mayr, I.; Baumann, U.; Huber, R.; Stone, S. R.; Hofsteenge, J. EMBO J. 1989, 8, 3467.
28. (c) Kettner, C.; Shaw, E. Thromb. Res. 1979, 14, 969.
29. 14. (a) Morgan, B. A.; Gainor, J. A. In Ann. Rep. Med. Chem. Allen, R. C., Ed.; Academic: San Diego, 1989; vol. 24, Chapter 26, pp 243-252. 8.
30. (b) Spatola, A. F. in Chemistry and Biochemistry of Amino Acids, Peptides ands Proteins; Weinstein, B., Ed.; Marcel Dekker: New York, 1983; vol. 7, Chapter 5.
31. (c) Rich, D. H. in Comprehensive Medicinal Chemistry, Hansch, C.; Sammes, P. G.; Taylor, J. B., Eds.; Pergamon: Oxford, 1990; Vol. 2, Chapter 8.
32. 15. All new compounds were characterized by full spectroscopic (NMR, IR, low/high resolution MS) data. Yields refer to spectroscopically and chromatographically homogenous (≥95% by HPLC, TLC) materials.
33. 16. Tamura, S. Y.; Semple, J. E.; Ardecky, R. J.; Leon, P.; Carpenter, S. H.; Ge, Y.; Shamblin, B. M.; Weinhouse, M. I.; Ripka, W. C.; Nutt, R. F. Tetrahedron Lett. 1996, 37, 4109.
34. 17. Dagnino, R.; Webb, T. R. Tetrahedron Lett. 1994, 35, 2125.
35. 18. Esterase approach, see: (a) Morimoto, Y; Terao, Y.; Achiwa, K. Chem. Pharm. Bull. 1987, 35, 2266.
36. (b) Bjorkling, F.; Boutelje, J.; Gatenbeck, S.; Hult, K.; Norin, T. Appl. Microbiol. Biotechnol. 1985, 21, 16. Classical resolution approach:
37. (c) Applequist, D. E.; Werner, N. D. J. Org. Chem. 1963, 28, 48.
38. (d)Werner, A.; Conrad, H. E. Ber. 1899, 52, 3046.
39. (e) For a current report on similar problems and strategies see: Hulme, S. J.; Jenkins, P. R.; Fawcett, J.; Russell, D. R. Tetrahedron Lett. 1994, 35, 5501.
40. 19. In vitro enzyme assays were performed according to the protocols described in reference 11.